Search Results

Featured Stories

Toggle

Showing 25 of 2011 results

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Teva Announces Changes to Executive Management Team

Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

Teva Settles Price Fixing Charges With U.S. DOJ

Teva Reports Second Quarter 2023 Financial Results

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development

Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership

Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023

Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients

Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

Teva Concludes Nationwide Opioids Settlement Agreement

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Teva Launches New “Pivot to Growth” Strategy

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

Teva to Launch New Growth Strategy at Investor Day

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023

Complete Response Letter Received for AVT02 Biologics License Application